Market Intelligence, Clinical Progress, and High-Purity Reagents for ER+ Breast Cancer and Endocrine Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ESR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ESR1 Recombinant LBD & Full-Length Protein (WT & Mutants: Y537S, D538G, E380Q) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. |
View ESR1 Products |
| Gene Delivery | ESR1 Promise-ORF / Lentivirus Full-length ORF for stable reporter cell line construction. |
View ESR1 Products |
| Benchmark Ab | Anti-ESR1 (Benchmark Sequence/Clinical Grade) Recombinant positive control for Western/IP/IHC. |
View ESR1 Products |
| Validator | ESR1 siRNA Set For knockdown verification and specificity controls. |
View ESR1 Products |
| Related Target A | PGR (Progesterone Receptor) Co-regulated hormone receptor in breast cancer; essential for combination biomarker studies. |
View PGR Products |
| Related Target B | CDK4 CDK4/6 inhibition is standard-of-care combination with endocrine therapy; critical for synergy assays. |
View CDK4 Products |
| Related Target C | PIK3CA Frequently co-mutated; drives endocrine resistance pathways. |
View PIK3CA Products |
| Related Target D | ESR2 (ER-beta) Counter-screening for alpha-selectivity assessment. |
View ESR2 Products |
| Related Target E | HER2 (ERBB2) Combination therapy target in HR+/HER2+ breast cancer. |
View HER2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ESR1 Acquired Resistance Mutations (Y537S, D538G, E380Q) | Purified WT and Mutant LBD Proteins (>95% purity, Sequence Verified) for selectivity binding and reporter assays |
| ERβ (ESR2) Off-Target Selectivity Screening | Homolog Panel: ESR1 vs. ESR2 Proteins strictly verified by mass spec for counter-screening |
| Cell-Based Transcriptional Activity & Degradation | ESR1 Lentivirus Particles for stable luciferase reporter cell lines; preserves native conformation |
| Cross-Species Cynomolgus / Mouse Efficacy Evaluation | Human / Mouse / Cyno ortholog proteins available with >95% purity and confirmed sequence identity |
| Lack of Specificity Controls | Validated ESR1 siRNA and Clinical Benchmark Antibodies included for knockdown and target engagement confirmation |
Live ESR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ESR1 therapeutics is intensifying, with major players shifting focus from traditional SERMs and intramuscular SERDs to next-generation oral SERDs, PROTAC degraders, and covalent antagonists (CERANs). As first-generation oral SERDs such as elacestrant enter the clinic and vepdegestrant (PROTAC) advances in Phase 3, the next wave of R&D is targeting ESR1 mutant-specific acquired resistance (e.g., Y537S, D538G, E380Q) and rational combination with CDK4/6 and PI3K/AKT inhibitors. High-purity mutant recombinant proteins and stable cell lines are essential to validate these next-generation modalities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Oral SERD | Menarini / Radius (Elacestrant), AstraZeneca (Camizestrant), Roche (Giredestrant), Eli Lilly (Imlunestrant) | ER+/HER2- Advanced / Metastatic Breast Cancer | Mutant vs. WT Binding Selectivity (Need purified ESR1 WT / Y537S / D538G LBD proteins) |
| PROTAC Degrader | Arvinas / Pfizer (Vepdegestrant) | ER+ Metastatic Breast Cancer (post-CDK4/6) | Ternary Complex Formation & Cellular Degradation (Need ESR1 protein + stable cell line) |
| Covalent Antagonist (CERAN) | Sumitomo Pharma / H3 Biomedicine (H3B-6545) | ER+ Breast Cancer | Covalent Binding & Mutant Activity (Need purified WT and mutant ESR1 LBD) |
| Combination (SERD + CDK4/6 or PI3K) | Multiple Big Pharma | ER+ Breast Cancer, Endometrial Cancer | Pathway Assays (Need PGR, CDK4, PIK3CA reagents for combination screening) |